{"id":"https://openalex.org/W2898780717","doi":"https://doi.org/10.1212/wnl.88.16_supplement.p2.025","title":"Pharmacologic Characteristics of Valbenazine (NBI-98854) and its Metabolites (P2.025)","display_name":"Pharmacologic Characteristics of Valbenazine (NBI-98854) and its Metabolites (P2.025)","publication_year":2017,"publication_date":"2017-04-18","ids":{"openalex":"https://openalex.org/W2898780717","doi":"https://doi.org/10.1212/wnl.88.16_supplement.p2.025","mag":"2898780717"},"language":"en","primary_location":{"id":"doi:10.1212/wnl.88.16_supplement.p2.025","doi":"https://doi.org/10.1212/wnl.88.16_supplement.p2.025","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1212/wnl.88.16_supplement.p2.025","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"},"volume":null,"type":"article","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5113490804","display_name":"Dimitri E. Grigoriadis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I67391869","display_name":"Neurocrine Biosciences (United States)","ror":"https://ror.org/05d84mm26","country_code":"US","type":"company","lineage":["https://openalex.org/I67391869"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dimitri Grigoriadis","raw_affiliation_strings":["Neurocrine Biosciences, Inc. San Diego CA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurocrine Biosciences, Inc. San Diego CA United States","institution_ids":["https://openalex.org/I67391869"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5111610526","display_name":"Evan Smith","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I67391869","display_name":"Neurocrine Biosciences (United States)","ror":"https://ror.org/05d84mm26","country_code":"US","type":"company","lineage":["https://openalex.org/I67391869"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Evan Smith","raw_affiliation_strings":["Neurocrine Biosciences, Inc. San Diego CA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurocrine Biosciences, Inc. San Diego CA United States","institution_ids":["https://openalex.org/I67391869"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103016180","display_name":"Ajay Madan","orcid":"https://orcid.org/0000-0002-8563-2546","observed_orcids":["https://orcid.org/0000-0002-8563-2546"]},"institutions":[{"id":"https://openalex.org/I67391869","display_name":"Neurocrine Biosciences (United States)","ror":"https://ror.org/05d84mm26","country_code":"US","type":"company","lineage":["https://openalex.org/I67391869"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Ajay Madan","raw_affiliation_strings":["Neurocrine Biosciences, Inc. San Diego CA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurocrine Biosciences, Inc. San Diego CA United States","institution_ids":["https://openalex.org/I67391869"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5113490804","display_name":"Dimitri E. Grigoriadis","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I67391869","display_name":"Neurocrine Biosciences (United States)","ror":"https://ror.org/05d84mm26","country_code":"US","type":"company","lineage":["https://openalex.org/I67391869"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Dimitri Grigoriadis","raw_affiliation_strings":["Neurocrine Biosciences, Inc. San Diego CA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurocrine Biosciences, Inc. San Diego CA United States","institution_ids":["https://openalex.org/I67391869"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5071108330","display_name":"Clinton Wright","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I67391869","display_name":"Neurocrine Biosciences (United States)","ror":"https://ror.org/05d84mm26","country_code":"US","type":"company","lineage":["https://openalex.org/I67391869"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Clinton Wright","raw_affiliation_strings":["Neurocrine Biosciences, Inc. San Diego CA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurocrine Biosciences, Inc. San Diego CA United States","institution_ids":["https://openalex.org/I67391869"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5069536436","display_name":"Haig P. Bozigian","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I67391869","display_name":"Neurocrine Biosciences (United States)","ror":"https://ror.org/05d84mm26","country_code":"US","type":"company","lineage":["https://openalex.org/I67391869"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Haig Bozigian","raw_affiliation_strings":["Neurocrine Biosciences, Inc. San Diego CA United States"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Neurocrine Biosciences, Inc. San Diego CA United States","institution_ids":["https://openalex.org/I67391869"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":1,"corresponding_author_ids":[],"corresponding_institution_ids":["https://openalex.org/I67391869"],"apc_list":null,"apc_paid":null,"fwci":0.3811,"has_fulltext":false,"cited_by_count":2,"citation_normalized_percentile":{"value":0.65829586,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":{"min":94,"max":96},"biblio":{"volume":"88","issue":"16_supplement","first_page":null,"last_page":null},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.6371999979019165,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10085","display_name":"Parkinson's Disease Mechanisms and Treatments","score":0.6371999979019165,"subfield":{"id":"https://openalex.org/subfields/2728","display_name":"Neurology"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10375","display_name":"Pharmacogenetics and Drug Metabolism","score":0.14720000326633453,"subfield":{"id":"https://openalex.org/subfields/3004","display_name":"Pharmacology"},"field":{"id":"https://openalex.org/fields/30","display_name":"Pharmacology, Toxicology and Pharmaceutics"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10077","display_name":"Neuroscience and Neuropharmacology Research","score":0.05139999836683273,"subfield":{"id":"https://openalex.org/subfields/2804","display_name":"Cellular and Molecular Neuroscience"},"field":{"id":"https://openalex.org/fields/28","display_name":"Neuroscience"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/valbenazine","display_name":"valbenazine","score":0.9990000128746033},{"id":"https://openalex.org/keywords/drug-metabolites","display_name":"drug metabolites","score":0.734000027179718},{"id":"https://openalex.org/keywords/in-vitro-metabolism","display_name":"in vitro metabolism","score":0.6890000104904175}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5840561985969543},{"id":"https://openalex.org/C2777667586","wikidata":"https://www.wikidata.org/wiki/Q8038170","display_name":"Wright","level":2,"score":0.5228565335273743},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.40125492215156555},{"id":"https://openalex.org/C95457728","wikidata":"https://www.wikidata.org/wiki/Q309","display_name":"History","level":0,"score":0.1313355565071106},{"id":"https://openalex.org/C52119013","wikidata":"https://www.wikidata.org/wiki/Q50637","display_name":"Art history","level":1,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1212/wnl.88.16_supplement.p2.025","doi":"https://doi.org/10.1212/wnl.88.16_supplement.p2.025","is_oa":false,"landing_page_url":"http://dx.doi.org/10.1212/wnl.88.16_supplement.p2.025","pdf_url":null,"source":{"id":"https://openalex.org/S79704628","display_name":"Neurology","issn_l":"0028-3878","issn":["0028-3878","1526-632X"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-2","medline","norway-2","poland-140","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Neurology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"pdf":false,"grobid_xml":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W2607267818","https://openalex.org/W2609547445","https://openalex.org/W4311933743","https://openalex.org/W2589879184","https://openalex.org/W2792337029","https://openalex.org/W3008202300","https://openalex.org/W7212059498","https://openalex.org/W4200053241","https://openalex.org/W2792080063","https://openalex.org/W2793700294"],"abstract_inverted_index":{"Objective:":[0],"To":[1],"characterize":[2],"the":[3,21,32,73,111,269,283,299],"pharmacology":[4],"of":[5,34,75,83,99,106,152,159,289,302,364,369],"valbenazine":[6,76,126,208,253,303],"and":[7,60,77,90,127,137,168,178,199,245,254,259,286,304],"its":[8,78,128,305],"metabolites":[9,79,129,306],"in":[10,29,87,157],"vitro":[11],".":[12],"Background:":[13],"Valbenazine":[14,52,177],"(NBI-98854),":[15],"a":[16,61,118,149,188,361],"novel":[17,310],"compound":[18],"that":[19,146,252,308],"inhibits":[20],"vesicular":[22],"monoamine":[23],"transporter":[24,112],"2":[25,294],"(VMAT2),":[26],"is":[27,360],"currently":[28],"development":[30],"for":[31,130,271,317,334,349,378,393,405],"treatment":[33],"tardive":[35],"dyskinesia":[36],"\u2013":[37],"an":[38,341,356,385,412],"often":[39],"persistent":[40],"movement":[41,319],"disorder":[42],"induced":[43],"by":[44],"chronic":[45],"exposure":[46],"to":[47,71,80,102,124,165,174,187,196,203,279],"dopamine":[48,109,228],"receptor":[49,234,266],"blocking":[50],"agents.":[51],"has":[53,330,345,374,389,401],"two":[54],"major":[55],"metabolites:":[56],"R,R,R-dihydrotetrabenazine":[57],"((+)-\u03b1-DHTBZ,":[58],"NBI-98782)":[59],"mono-oxy":[62],"metabolite":[63],"(NBI-136110).":[64],"Design/Methods:":[65],"Radioligand":[66,142],"binding":[67,82,143,156],"studies":[68,144,292],"were":[69],"conducted":[70,123],"assess":[72],"ability":[74,98],"inhibit":[81,103,256],"[":[84,153],"3":[85,154,297],"H]-DHTBZ":[86,155],"rat":[88,160],"striatum":[89,161],"human":[91,169],"platelet":[92],"homogenates,":[93],"expressing":[94],"VMAT2":[95,257,311],"protein.":[96],"The":[97],"these":[100],"molecules":[101],"functional":[104],"uptake":[105],"serotonin":[107,217],"or":[108,227,236],"via":[110],"was":[113,122,148],"also":[114,180],"evaluated.":[115],"In":[116,277],"addition,":[117],"broad":[119],"panel":[120],"screen":[121],"test":[125],"off-target":[131,214],"interactions":[132,215,262],"at":[133,216,237,263],">80":[134],"receptor,":[135],"transporter,":[136],"ion":[138,246],"channel":[139],"sites.":[140],"Results:":[141],"showed":[145],"R,R,R-DHTBZ":[147,192,210,255],"potent":[150],"inhibitor":[151,312],"homogenates":[158],"(K":[162,171,193],"i":[163,172,194,201],"=1.0":[164],"2.8":[166],"nM)":[167],"platelets":[170],"=2.6":[173],"3.3":[175],"nM).":[176],"NBI-136110":[179],"exhibited":[181,211],"inhibitory":[182],"effects":[183],"on":[184],"VMAT2,":[185],"but":[186],"lesser":[189],"degree":[190],"than":[191],"=110":[195],"190":[197],"nM":[198],"K":[200],"=160":[202],"220":[204],"nM,":[205],"respectively).":[206],"Neither":[207],"nor":[209],"any":[212],"significant":[213],"(5-HT":[218],"1A":[219],",":[220,223],"5-HT":[221,224],"2A":[222],"2B":[225],")":[226,233],"(D":[229],"1":[230],"\u2013D":[231],"4":[232],"sites,":[235,267],"other":[238,264],"protein":[239],"targets":[240],"including":[241],"G-protein-coupled":[242],"receptors,":[243],"transporters,":[244],"channels.":[247],"Conclusions:":[248],"These":[249],"results":[250,288],"indicate":[251],"selectively":[258],"specifically,":[260],"without":[261],"non-specific":[265],"suggesting":[268],"potential":[270,316],"fewer":[272],"unwanted":[273],"clinical":[274,291],"side":[275],"effects.":[276],"addition":[278],"being":[280],"consistent":[281],"with":[282,336,351,380,395,407],"favorable":[284],"efficacy":[285],"tolerability":[287],"recent":[290],"(KINECT":[293],"[NCT01733121],":[295],"KINECT":[296],"[NCT02274558]),":[298],"pharmacologic":[300],"characteristics":[301],"suggest":[307],"this":[309,370],"may":[313],"have":[314],"therapeutic":[315],"various":[318],"disorders.":[320],"Study":[321],"Supported":[322],"by:":[323],"Neurocrine":[324,337,352,365,381,396,408],"Biosciences,":[325,338,397,409],"Inc.":[326,339,354,383,398,410],"Disclosure:":[327],"Dr.":[328,343,358,372,387,399],"Grigoriadis":[329,373],"received":[331,346,375,390,402],"personal":[332,347,376,391,403],"compensation":[333,348,377,392,404],"activities":[335,350,379,394,406],"as":[340,355,384,411],"employee.":[342,357,386,413],"Smith":[344],"Bioscience,":[353,366,382],"Madan":[359],"former":[362],"employee":[363],"Inc.,":[367],"sponsor":[368],"study.":[371],"Wright":[388],"Bozigian":[400]},"counts_by_year":[{"year":2017,"cited_by_count":2}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2018-11-09T00:00:00"}